As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals.
Gilead partners with various organizations that support people living with breast cancer. One such organization, the Young Survival Coalition (YSC), recognizes the unique needs of people of childbearing age and works with patients under 40.
For the past 30 years, Pilar Fernandez has navigated living with metastatic breast cancer. And while she’s faced a series of related health challenges, it hasn’t slowed her down.
When employees at Gilead’s recently opened New Jersey office need a place to meet, the “Cara” conference room is one such place they gather. Given the room’s namesake, it’s especially fitting when the topic at hand is the company’s oncology work.
Gilead Sciences, Inc. (Nasdaq: GILD) announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year.
When Shirley Cantin was a law student, about half of her classmates were women. Yet when she joined a corporate law firm, Shirley noticed that most of its leaders were white men. And when she left a decade later, little progress on the leadership team’s diversity had been made.
Gilead Sciences, Inc. announced it will present new data at San Antonio Breast Cancer Symposium 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients.
Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating a new panel made sense for a company dedicated to helping end the HIV epidemic.
Through our community partnerships in low-and-middle-income countries, we are working together to expand access and reduce barriers to care while embracing innovation.
We're proud to have contributed to this milestone announced by the World Health Organization - marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh.
Since the pledge, Gilead has continued its long history in supporting reducing deaths from VL and controlling other neglected tropical diseases such as cryptococcal meningitis in efforts to advance global health equity.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...